• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Policy

At confirmation hearing for Trump’s HHS nominee, drug pricing takes center-stage

January 10, 2018 By Sarah Faulkner

capitol hill

Alex Azar, the president’s nominee to head the Dept. of Health & Human Services, has nearly a decade of experience in the pharmaceutical industry – and that experience is either predictive of his inability to act on lowering drug prices or will serve him well as HHS chief, depending on who you ask. At Azar’s […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Eli Lilly & Co.

Report: Drugmakers may have ducked $1.3B in Medicaid rebates

December 21, 2017 By Sarah Faulkner

CMS

Without calling out any drug companies by name, the U.S. Dept. of Health and Human Services’ Office of Inspector General revealed this week that 10 potentially misclassified drugs may have resulted in $1.3 billion in lost rebates to Medicaid between 2012 and 2016. The issue of ducking rebates came to the public’s attention earlier this […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS)

Governor passes law to keep birth control free in Massachusetts

November 22, 2017 By Sarah Faulkner

Prescription drugs

Massachusetts governor Charlie Baker signed a law on Monday requiring health insurers to cover at least one kind of every type of FDA-approved birth control. The new law protects health care services and rights for women across the state, “irrespective of what goes on in Washington,” the Republican governor said at the bill’s signing, according […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Policy, Wall Street Beat, Women's Health Tagged With: FDA

Trump’s opioid public health emergency highlights differences with FDA

October 27, 2017 By Sarah Faulkner

capitol hill

President Donald Trump yesterday declared the opioid epidemic a national public health emergency – a move that he said will help “liberate our communities from this scourge of drug addiction.” The president, surrounded by lawmakers and advocates, said that the government’s plan to fight the opioid epidemic would include “really tough, really big, really great […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Wall Street Beat Tagged With: Endo Pharmaceuticals

CDC: Overdose-related deaths in 2016 surpassed death count from peak of AIDS crisis

October 13, 2017 By Sarah Faulkner

CDC

More than 63,000 people died from a drug overdose last year – that’s more than the number of deaths caused by AIDS in 1995, according to data from the Centers for Disease Control and Prevention. Between 2015 and 2016, the number of people who died from a drug overdose involving illicitly-manufactured fentanyl, a synthetic opioid, more […]

Filed Under: Featured, Policy Tagged With: Centers for Disease Control & Prevention

Ethics watchdog: Rep. Collins broke rules by advocating for biotech

October 13, 2017 By Sarah Faulkner

Capitol Hill

There’s “substantial reason to believe” that Rep. Chris Collins (R-NY) broke federal law and congressional rules by sharing insider information to spur investment and by meeting with government researchers to advocate for Innate Immunotherapeutics (ASX:IIL) – an Australian biotech that he’s invested in. The Republican lawmaker recruited a number of investors for the company, including Dr. […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: innateimmunotherapeutics

Update: Industry panels disintegrate in wake of Trump remarks

August 16, 2017 By Sarah Faulkner

capitol hill

A pair of industry panels convened by President Donald Trump disintegrated today in the wake of his latest comments on the racist violence in Charlottesville. After Merck (NYSE:MRK) CEO Kenneth Frazier announced on Monday that he planned to leave Trump’s manufacturing advisory panel, a wave of executives followed in his path. Today, reversing from a statement […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, johnsonandjohnson, Medtronic, Merck

Merck CEO Frazier leaves Trump council

August 14, 2017 By Sarah Faulkner

Merck

Merck (NYSE:MRK) announced today that chief executive Kenneth Frazier plans to resign from President Donald Trump’s American Manufacturing Council, citing the president’s mild-mannered response to a white nationalist rally in Virginia on Saturday. The “Unite The Right” gathering turned deadly when a car mowed down a group of counter-protesters, killing at least one person and injuring […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Merck

Trump declares national emergency over opioid epidemic

August 11, 2017 By Sarah Faulkner

Pills

President Trump said yesterday that he is preparing to declare the opioid epidemic a national emergency. This is a reversal from an announcement made earlier this week by Health and Human Services Secretary Tom Price, who said that they would not declare a state of emergency. “The opioid crisis is an emergency, and I’m saying […]

Filed Under: Featured, Pain Management, Pharmaceuticals, Policy Tagged With: Capitol Hill

Drugmakers talk competition & innovation with FDA leaders

July 19, 2017 By Sarah Faulkner

FDA

Drugmakers, payers and patient advocates convened at the FDA’s White Oak campus yesterday to present before a panel of regulatory leaders about competition and innovation in the pharmaceutical industry. The meeting, which was titled “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access,” opened with FDA commish Scott Gottlieb, who announced that the […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Regulatory/Compliance, Wall Street Beat

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS